Merck Reports Updated KEYNOTE-811 Data for Keytruda in HER2-Positive Gastric Cancer

Merck today presented updated data from the Phase 3 KEYNOTE-811 trial evaluating Keytruda (pembrolizumab) plus trastuzumab and chemotherapy in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma. The updated data showed a significant improvement in overall survival with the Keytruda combination compared to trastuzumab and chemotherapy alone. The median overall survival was 20.0 months in the Keytruda arm compared to 16.8 months in the control arm.